Correction to: The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion

Sophie Park; Charikleia Kelaidi; Mathieu Meunier; Nicole Casadevall; Aaron T Gerds; Uwe Platzbecker

doi:10.1007/s00277-019-03874-w

Correction to: The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion

Ann Hematol. 2020 Jan;99(1):21. doi: 10.1007/s00277-019-03874-w.

Authors

Sophie Park¹, Charikleia Kelaidi², Mathieu Meunier³, Nicole Casadevall⁴, Aaron T Gerds⁵, Uwe Platzbecker⁶

Affiliations

¹ CHU Grenoble, Université Grenoble Alpes, Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, CS 10217, 38043, Grenoble, France. spark@chu-grenoble.fr.
² Aghia Sophia Children's Hospital, Athens, Greece.
³ CHU Grenoble, Université Grenoble Alpes, Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, CS 10217, 38043, Grenoble, France.
⁴ Hôpital Saint-Antoine, Paris, France.
⁵ Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
⁶ Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany.

Abstract

This article was originally published without an Open Access but due to the authors final decision to opt for Open Choice this correction was created.

Publication types

Published Erratum